Laser In Situ Fenestration Study

Description

The goal of this clinical trial is to learn about a new device, named the LIFE device, to treat people with aneurysms (swellings) in the aorta (large, main blood vessel that delivers blood from the heart to the body). The main questions this trial aims to answer are: * If the LIFE device works to treat aortic aneurysms * What medical problems participants have when the LIFE device is used Participants will undergo treatment with the LIFE device and thereafter at 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years have their pulses checked, bloodwork to check kidney function (BUN and serum creatinine), and a CT scan of the aneurysm area.

Conditions

Aortic Aneurysm, Endovascular Aneurysm Repair

Study Overview

Study Details

Study overview

The goal of this clinical trial is to learn about a new device, named the LIFE device, to treat people with aneurysms (swellings) in the aorta (large, main blood vessel that delivers blood from the heart to the body). The main questions this trial aims to answer are: * If the LIFE device works to treat aortic aneurysms * What medical problems participants have when the LIFE device is used Participants will undergo treatment with the LIFE device and thereafter at 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years have their pulses checked, bloodwork to check kidney function (BUN and serum creatinine), and a CT scan of the aneurysm area.

Laser In Situ Fenestration for Endovascular Aortic Repair (LIFE) Study

Laser In Situ Fenestration Study

Condition
Aortic Aneurysm
Intervention / Treatment

-

Contacts and Locations

Columbia

University of Missouri - Columbia, Columbia, Missouri, United States, 65212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Aortic aneurysm \>5.5 cm in a man or \> 5.0 cm in a woman or rapid expansion deemed at significant risk for rupture in the juxtarenal or pararenal aorta.
  • 2. Endovascular aortic repair requiring coverage of renovisceral branches.
  • 3. Not candidate or at high risk for open repair. For example, but not exclusively, due to renal dysfunction, previous abdominal surgery, obese body habitus, previous coronary bypass grafts or high cardiac risk, chronic obstructive pulmonary disease (COPD) or on oxygen at rest, poorly controlled diabetes, current smoking, or antiplatelet or anticoagulation use.
  • 4. Proximal aortic landing zone in Zone 5 of the aorta or previous graft of at least 10 mm in length and diameter of between 20 and 40 mm.
  • 5. Distance ≥ 5 mm between top of graft fabric and renovisceral branch orifice.
  • 6. At least a 5 mm iliofemoral artery to accept the endovascular stent graft device and an axillary brachial artery of sufficient diameter to accept the laser catheter.
  • 7. Renovisceral diameter between 4 and 13 mm at the origin.
  • 8. At the time of case planning, the patient's anatomy appears amenable to complete exclusion of the aneurysm with laser fenestration techniques.
  • 9. Not willing or able to travel to sites that have access to manufacturer-made investigational endovascular devices.
  • 10. Not a candidate for currently approved endovascular options.
  • 11. 18 years or older.
  • 12. Patient or legally authorized representative agrees to participate in the study and provides written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.
  • 13. Patient is able and willing to meet all study requirements, including participating in follow up evaluations and attending required assessment visits.
  • 1. Known sensitivities or allergies to the materials of construction of the devices, including Nitinol, polyester, Platinum-Iridium, stainless steel, fluoropolymer, and heparin.
  • 2. Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed.
  • 3. Uncorrectable coagulopathy.
  • 4. Body habitus that would inhibit radiographic visualization of the aorta or exceeds the safe capacity of equipment.
  • 5. Concurrent participation in another research protocol for investigation of an experimental therapy.
  • 6. Subject has been judged to be unsuitable for participation in the study by the Investigator for any reason.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jonathan Bath,

Jonathan Bath, MD, PRINCIPAL_INVESTIGATOR, University of Missouri School - Columbia

Study Record Dates

2031-06